Coherus Oncology (CHRS) EBIT Margin (2013 - 2026)

Coherus Oncology has disclosed EBIT Margin across 13 years of filings, most recently posting 293.67% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 293.67%, up 30424.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 62.22% (up 49744.0% YoY), and the FY2025 annual result was 91.19%, up 66539.0% from the prior year.
• EBIT Margin came in at 293.67% for Q1 2026 at Coherus Oncology, down from 759.32% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 759.32% in Q4 2025 to a low of 2937.05% in Q1 2024.
• The 5-year median for EBIT Margin is 208.86% (2023), against an average of 383.9%.
• Across the five-year window, EBIT Margin tumbled 272819 bps in 2024 and surged 233914 bps in 2025, its largest moves.
• Coherus Oncology's EBIT Margin stood at 113.54% in 2022, then soared by 34 bps to 75.29% in 2023, then sank by 680 bps to 586.89% in 2024, then surged by 229 bps to 759.32% in 2025, then sank by 139 bps to 293.67% in 2026.
• The last three EBIT Margin figures came in at 293.67% (Q1 2026), 759.32% (Q4 2025), and 383.14% (Q3 2025), per Business Quant data.